Background Sex-based differences in immune response are well established, but whether men and women derive comparable benefit ...
Targeting LAG-3 and TIGIT did not improve efficacy compared with enfortumab vedotin plus pembrolizumab in advanced urothelial cancer. In patients with locally advanced or metastatic urothelial cancer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results